Overview
Urea cycle disorders (UCDs) are dramatic congenital inherited metabolic disorders. There is no cure. Many novel therapeutic approaches are currently being developed, which hopefully will change the current situation. Testing the efficacy of such new therapies in patients is a challenge, because many clinical parameters are influenced by several disturbances and biochemical parameters are often not very specific.
The measurement of ureagenesis is a tool to analyze the entire function of the urea cycle in a single test. This is more meaningful for the characterization of UCD patients than the analysis of single metabolites or enzymes. Therefore, the test will be important to evaluate current and future novel therapies.
The term "ureagenesis" means "production of urea", which is the main task of the urea cycle. This total urea production can be measured with a "tracer" (in this case a stable ammonium chloride isotope). This tracer is non-radioactive and non-toxic. It is for example used as an unmarked substance in cough syrup, diuretic drugs and as food additive. Thus, the tracer does not pose a risk to the participant, especially since only a very low dose is applied.
The investigators will analyze specific substances from the urea cycle (namely [15N, 14N] urea and several [15N] amino acids) that are produced during the test and compare them with results from healthy people. The maximum test duration is 5 hours.
This project is being carried out at one site, namely the University Children's Hospital in Zurich.
This project is being carried out under Swiss law. The responsible Ethics Committee has reviewed and approved the study.
Description
The term "we" was exchanged by "The investigators" as recommended.
Eligibility
Inclusion Criteria:
- healthy subjects at any age and given written informed consent
- subjects with a UCD confirmed by genetic or enzymatic diagnostics at any age and given written informed consent
Exclusion Criteria:
- healthy subjects with acute and chronic disease requiring treatment of any kind
- pregnant or lactating women.
- UCD patients with acute and chronic (other than her/his UCD) disease requiring treatment
- UCD patients in which intake of carglumic acid cannot be stopped for 24 hours prior to the test